Solstice Oncology launched with a $225 million Series A led by RA Capital to advance Harbour BioMed-licensed porustobart into neoadjuvant MSS colon cancer.
Newsletter
Pipeline, markets, policy, and science. Once a week.
KRAS sat on the undruggable list for decades. Silexion's SIL204 is built to silence the mutation earlier in the cell, and the Phase 2/3 program is now moving into patients.
uniQure asked FDA for accelerated approval of AMT-130 on a 12-patient, 36-month high-dose dataset, after the agency twice reversed itself on external-control evidence.
A pre-specified VESALIUS-CV analysis found evolocumab cut all-cause death by 20% in high-risk primary prevention, with the benefit appearing only after 1.5 years and a 1.8-point absolute gap at five years.